Review of “Promoting Transparency in Pharmaceutical Industry–Sponsored Research” (Ross et al., American Journal of Public Health, 2012)
This article by Joseph S. Ross, Cary P. Gross, and Harlan M. Krumholz systematically examines how pharmaceutical industry sponsorship distorts clinical trial research and the medical literature. It focuses on practices that obscure information relevant to patients and physicians, undermining evidence-based medicine. The authors argue for greater transparency through improved disclosure, comprehensive trial registration, and independent data analysis.
While this study applies to all medicine unfortunately, it is particularly applicable to psychiatry which seems to have embraced these practices with open arms.
Key Ways Industry (and by Extension Psychiatry/Pharma) Distorts Scientific Trials
The paper highlights that while some overt manipulations have declined due to IRBs and better information access, several practices remain common:
- Seeding Trials These are clinical trials primarily designed for marketing rather than genuine scientific inquiry. They promote recently approved or pending drugs by involving practicing physicians as “investigators,” giving them hands-on experience with the product to encourage prescribing. The trials appear scientific but prioritize marketing objectives.
- Publication Planning and Messaging Companies develop coordinated strategies to shape the scientific literature. This includes “ghostwriting,” where industry hires professional writers to draft articles that are then published under academic authors’ names, often with minimal or no disclosure of the true contributions. The goal is to control the narrative and emphasize favorable messages about the product.
- Selective Publication and Reporting of Trial Outcomes This is one of the most pervasive issues. Companies may: 1) Withhold entire negative or unfavorable trials from publication. 2) Selectively report only positive outcomes while omitting negative or neutral data. 3) Engage in outcome switching or selective emphasis in publications.
The result is a biased medical literature that overstates benefits and understates risks.
The authors note broader context: Industry-sponsored trials have 3.5 times greater odds of reporting pro-industry conclusions (from meta-analyses). Examples span therapeutic areas, including antidepressants and antipsychotics relevant to psychiatry (e.g., selective serotonin reuptake inhibitors for depression, antipsychotics for schizophrenia).
Additional Historical/Contextual Distortions Mentioned
- Comparing drugs to inferior or high-dose active controls to inflate apparent efficacy or tolerability.
- “Salami slicing” (publishing multiple papers from the same dataset), though less common now.
- Inappropriate authorship and lack of accountability.
These practices are enabled by marketing’s influence on research, with collaborations between academia and industry sometimes blurring lines.
Proposed Solutions for Transparency
- Improved Disclosure: Full reporting of investigator contributions, funding sources, and roles (including ghostwriters).
- Comprehensive Trial Registration: All trials publicly registered with detailed protocols and results.
- Independent Analysis: Third-party review of raw clinical trial data to verify findings.
The authors emphasize that while academic-industry partnerships are valuable for innovation, minimizing marketing’s impact on research is essential to protect the integrity of the medical literature and public health.
This 2012 paper remains a foundational reference on industry influence in clinical research, directly relevant to psychiatry given the heavy pharma involvement in psychotropic drug trials, guideline development, and promotion of models like chemical imbalance theories. It provides clear documentation of systemic falsification mechanisms through omission, commission, and manipulation.
Promoting Transparency in Pharmaceutical Industry–Sponsored Research” (Ross et al., American Journal of Public Health, 2012